Sonoma Pharmaceuticals Q2 FY27 net loss narrows 88% to $66,000

• Sonoma Pharmaceuticals’ second-quarter FY27 net loss narrowed 88% year over year to $66,000.
• Pretax earnings swung to $382,000, marking the first positive quarterly result in its history.
• Quarterly revenue rose 28% year over year to $7.17 million, while U.S. revenue jumped 93% to $2.8 million.
• A paid skincare co-formulation project could lead to a summer 2027 product launch if development succeeds and the partner accepts the formulation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sonoma Pharmaceuticals Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.